J9359 Loncastuximab tesirine-lpyl - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Loncastuximab tesirine-lpyl

Brand Name:

Zynlonta

Strength:

0.075mg

HCPCS:

J9359

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Drug Antibody Conjugate

Minor Drug Class:

CD19

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

March 25, 2022

CMS Discontinuation Date:

Status:

In Use